The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.
Since the introduction of novel therapeutic agents including thalidomide, lenalidomide and bortezomib, the prognosis of multiple myeloma (MM) has significantly improved. These agents have been incorporated into numerous treatment schedules for newly diagnosed as well as more advanced MM patients. Hence, the therapeutic options for MM have become more complex and subject to rapid changes. The multiple myeloma study group (MMSG) of the Belgian Hematological Society has established recommendations for the treatment of MM as based on an extensive review of the literature which is also summarized in this paper. The recommendations are the result of a consensus opinion between haematologists with experience in the field and representing most haematology centres in Belgium. Where applicable, reimbursement criteria are also taken into account. The consensus recommendations should be a reference for use by clinical haematologists in daily practice.
Schots
R
R
rik.shots@uzbrussel.be
Delforge
M
M
André
M
M
Bries
G
G
Caers
J
J
Demuynck
H
H
De Prijck
B
B
De Samblanx
H
H
Kentos
A
A
Meuleman
N
N
Offner
F
F
Vekemans
M C
MC
Vande Broek
I
I
Van Droogenbroeck
J
J
Van de Vanelde
A
A
Wu
K L
KL
Doyen
C
C
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001530:Belgium; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D016879:Salvage Therapy / Q000379:methods; D033581:Stem Cell Transplantation
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents